Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PPP5C | P53041 | 2/20 | 0.33 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.33 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25728480 | 1.00 | CCR2 (0.38) | CCR2KCNH2ATMCYP1A2TDP1 | |
| SCHEMBL799809 | 1.00 | CCR2 (0.38) | CCR2KCNH2ATMCYP1A2TDP1 | |
| SCHEMBL27627762 | 0.84 | CCR2 (0.34) | CCR2KCNH2 | |
| SCHEMBL27271348 | 0.84 | CCR2 (0.38) | CCR2KCNH2CYP1A2TDP1MMP1 | |
| SCHEMBL5307104 | 0.83 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL12108450 | 0.82 | CYP1A2 (0.39) | CCR2KCNH2CYP1A2TDP1MMP1 | |
| SCHEMBL13197230 | 0.82 | CYP1A2 (0.39) | CCR2KCNH2CYP1A2TDP1MMP1 | |
| SCHEMBL13448669 | 0.80 | CCR2 (0.37) | CCR2KCNH2CYP1A2TDP1MMP1 | |
| SCHEMBL14754513 | 0.80 | CCR2 (0.37) | CCR2KCNH2CYP1A2TDP1MMP1 | |
| SCHEMBL16003094 | 0.80 | CCR2 (0.37) | CCR2KCNH2CYP1A2TDP1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022052926-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 广州再极医药科技有限公司 | 2022-03-17 | — | — | WO | disclosed |
| EP-2830624-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9133147-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150038498-A1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME LLC | 2015-02-05 | — | — | US | disclosed |
| EP-2830624-A1 | THROMBIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-02-04 | — | — | EP | disclosed |
| WO-2013148478-A1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8093237-B2 | 11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazapine compounds; psychological disorders, sleep disorders; antipsychotic agents that modulate monoaminergic neurotransmitter receptor subtypes; side effect reduction | ARYX THERAPEUTICS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-08-12 | — | — | US | disclosed |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | PROTOCELL THERAPEUTICS INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | CCR2 3787/4885KCNH2 2547/4885ATM 2778/4885 |
| US-20150038498-A1 | THROMBIN INHIBITORS | F3, F2, CFH | CCR2 410/4885KCNH2 680/4885ATM 3765/4885 |
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | DBH, DRD4, PSEN1 | CCR2 4622/4885KCNH2 1234/4885ATM 3439/4885 |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | DBH, DRD4, PSEN1 | CCR2 4622/4885KCNH2 1234/4885ATM 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.